13.52% 0.2897

Acasti Pharma Inc (ACST)

Acasti Pharma Inc Aktie (ACST) Neueste Nachrichten

Acasti Pharma Inc (ACST)

Acasti Pharma Inc Aktie (ACST) Neueste Nachrichten

Acasti to Present at the Life Sciences Investor Forum - GlobeNewswire

Acasti to Present at the Life Sciences Investor Forum - StockTitan

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - GlobeNewswire

Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - StockTitan

Acasti Pharma (FRA:A1P0) EPS (Diluted) : €-1.32 (TTM As of Jun. 2024) - GuruFocus.com

Acasti Pharma (TSXV:ACST) 3-Year FCF Growth Rate : 34.20% (As of Jun. 2024) - GuruFocus.com

Acasti Pharma (TSXV:ACST) EPS (Diluted) : C$0.00 (TTM As of Jun. 2024) - GuruFocus.com

Acasti Pharma (TSXV:ACST) Enterprise Value : C$-16.76 Mil (As of Aug. 19, 2024) - GuruFocus.com

Acasti Pharma (TSXV:ACST) 50-Day SMA : C$N/A (As of Aug. 17, 2024) - GuruFocus.com

Acasti Pharma (TSXV:ACST) Financial Strength : 6 (As of Jun. 2024) - GuruFocus.com

Acasti Pharma (TSXV:ACST) 14-Day RSI : N/A (As of Aug. 17, 2024) - GuruFocus.com

Acasti Pharma Appoints Prashant Kohli as CEO with Incentives - TipRanks

Acasti Pharma (FRA:A1P0) Cash Flow from Investing : €0.10 Mil (TTM As of Jun. 2024) - GuruFocus.com

Acasti Pharma (FRA:A1P0) Earnings per Share (Diluted) : €-1.32 (TTM As of Jun. 2024) - GuruFocus.com

Acasti Pharma (STU:A1P0) 3-Year FCF Growth Rate : 34.20% (As of Jun. 2024) - GuruFocus.com

Acasti Pharma (FRA:A1P0) EV-to-Revenue : (As of Aug. 15, 2024) - GuruFocus.com

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 49.2% in July - Defense World

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update - GlobeNewswire

Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update - Yahoo Finance

Acasti Pharma Inc expected to post a loss of 34 cents a shareEarnings Preview - XM

Short Interest in Acasti Pharma Inc. (NASDAQ:ACST) Increases By 281.3% - Defense World

Acasti Pharma (NASDAQ:ACST) Stock Passes Above Two Hundred Day Moving Average of $2.99 - Defense World

Severe Hypertriglyceridemia Pipeline Insights (2024) | - openPR

Severe Hypertriglyceridemia Pipeline Insights (2024) | Clinical Trials, Latest Approvals, Treatment Options, Key Companies | 89bio, Acasti Pharma, Amarin Corporation, Arrowhead, Ionis Pharmaceuticals - Barchart

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 72.9% in June - Defense World

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Down 72.9% in June - American Banking and Market News

Quantisnow - Quantisnow

Acasti Pharma (NASDAQ:ACST) Shares Cross Above Two Hundred Day Moving Average of $2.98 - American Banking and Market News

Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year? - Yahoo Finance

New insider Adar1 Capital Management, Llc claimed ownership of 959,571 shares (SEC Form 3) - Quantisnow

Acasti Pharma GAAP EPS of -$0.09 misses by $0.01 (NASDAQ:ACST) - Seeking Alpha

FY2025 EPS Estimates for Acasti Pharma Inc. Increased by Analyst (NASDAQ:ACST) - Defense World

Brokers Issue Forecasts for Acasti Pharma Inc.’s Q1 2025 Earnings (NASDAQ:ACST) - Defense World

Is Acasti Pharma (NASDAQ:ACST) In A Good Position To Invest In Growth? - Yahoo Finance

Acasti reports 3Q loss - Yahoo New Zealand News

Acasti Pharma Inc. (NASDAQ:ACST) Short Interest Update - Defense World

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial - GlobeNewswire

Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial - StockTitan

Insiders At Acasti Pharma See Good Returns After Buying Stock Worth US$2.50m - Simply Wall St

Neptune, Acasti and NeuroBioPharm Announce Litigation Regarding its Former Chief Executive Officer - Yahoo Eurosport UK

Acasti Pharma (NASDAQ:ACST) Posts Quarterly Earnings Results, Beats Expectations By $0.30 EPS - Defense World

ACST Stock Earnings: Acasti Pharma Beats EPS for Q4 2024 - InvestorPlace

Acasti Announces Year-End 2024 Financial Results, Provides Business Update - GlobeNewswire

Acasti Announces Year-End 2024 Financial Results, Provides Business Update - StockTitan

Acasti Announces Year-End 2024 Financial Results, Provides Business Update - Yahoo Finance

Acasti Pharma (NASDAQ:ACST) Stock Price Passes Above Two Hundred Day Moving Average of $2.89 - Defense World

Acasti Pharma Inc expected to post a loss of 47 cents a shareEarnings Preview - XM

Acasti Pharma Inc. (NASDAQ:ACST) Sees Large Increase in Short Interest - Defense World

Acasti Pharma (NASDAQ:ACST) Stock Passes Above Two Hundred Day Moving Average of $2.81 - Defense World

Acasti Pharma to Attend BIO International Convention 2024 - GlobeNewswire

Acasti Pharma to Attend BIO International Convention 2024 - Yahoo Finance UK

Acasti Pharma (NASDAQ:ACST) Stock Price Crosses Below 200-Day Moving Average of $2.79 - Defense World

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom - Yahoo Finance

The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom - InvestorPlace

Insider Stock Buying Reaches US$2.50m On Acasti Pharma - Yahoo Canada Finance

Insider Stock Buying Reaches US$2.50m On Acasti Pharma - Yahoo Finance

Market Sentiment Around Loss-Making Acasti Pharma Inc. (CVE:ACST) - Yahoo Sport Australia

Acasti Pharma (NASDAQ:ACST) Stock Crosses Above Two Hundred Day Moving Average of $2.77 - Defense World

Has Acasti Pharma (ACST) Outpaced Other Medical Stocks This Year? - Yahoo Movies UK

Financial Comparison: ADC Therapeutics (NYSE:ADCT) vs. Acasti Pharma (NASDAQ:ACST) - Defense World

Acasti Pharma Inc. (NASDAQ:ACST) Sees Significant Decrease in Short Interest - Defense World

Proactive news headlines including Power Reit, Delta 9 Cannabis, Bragg Gaming and Acasti Pharma - The Globe and Mail

The 8 Best Stocks Under $2 To Buy For September 2024 ! - The Stock Dork

We're Keeping An Eye On Acasti Pharma's (NASDAQ:ACST) Cash Burn Rate - Simply Wall St

The Globe and Mail - The Globe and Mail

Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights - GlobeNewswire

Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial - GlobeNewswire

Why KeyCorp Shares Are Trading Lower By Over 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session - Benzinga

Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024 - GlobeNewswire

Ähnlich wie ACST